Clorox (NYSE: CLX) reported Q4 EPS of $1.66, $0.01 better than the analyst estimate of $1.65. Revenue for the quarter came in at $1.95 billion versus the consensus estimate of $1.91 billion.

GUIDANCE:

Clorox sees FY2027 EPS of $5.70-$6.00, versus the consensus of $5.52.

Net sales are expected to be up 13% to 14% compared to the prior year, including about 9.5 points of benefit from the GOJO acquisition. Organic sales are expected to increase about 3.5% to 4.5%, including more than 3.5 points of benefit from lapping the ERP-related drawdown in the prior fiscal year.

Gross margin is expected to be about 42%, reflecting higher-than-normal inflationary headwinds and negative mix more than offsetting the benefits from cost savings. This includes about 20 basis points of negative impact primarily related to the GOJO inventory step-up.

Selling and administrative expenses are expected to be about 16% of net sales. This includes about 40 basis points of negative impact from GOJO transaction-related costs.

Advertising and sales promotion spending is expected to be about 10% of net sales. This assumes over 11% of net sales for its retail businesses.

For earnings history and earnings-related data on Clorox (CLX) click here.